News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2024 Why is the immunology and inflammation market suddenly attracting a wave of investment? Discover why the immunology and inflammation market has recently been attracting a major wave of investment. July 30, 2024 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 14 Jun 2024Looking to cure type 1 diabetes with precision medicine Listen to our conversation with Diamyd Medical, working on precision medicine therapies for the prevention and treatment of type 1 diabetes. June 14, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 8 Mar 2024AI immune system mapping to boost drug discovery Immunai is using artificial intelligence to map the immune system. The company hopes this will lead to better and faster drug discovery. March 8, 2024 Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm Known throughout history for being home to the iconic scene of Hollywood, in recent years Los Angeles has also become a thriving biotech hub, after years of playing second fiddle in the U.S. to the likes of South San Francisco and Boston. In this article, we take a look at five of the best Los […] September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 Vitalli Bio formed to focus on immunological disorders Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Aditum Bio is a biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former president of the Novartis Institutes for BioMedical Research (NIBR) Mark Fishman. Vitalli Bio is being […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Affibody signs €20 million loan agreement Affibody Medical AB has received a €20 million ($21.2 million) venture debt loan facility from the European Investment Bank, EIB, backed by the InvestEU program. The investment will support Affibody’s research and development activities in Europe of the next-generation biopharmaceuticals targeting unmet medical needs in the immunology and oncology fields. “We are very pleased and […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Poolbeg influenza trial successfully completed Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […] December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Human Immunology Biosciences launches with $120M Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. HI-Bio was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices. Few targeted therapies exist for the autoimmune, allergic […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email